ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Autoinflammatory diseases"

  • Abstract Number: 0024 • ACR Convergence 2025

    Biobank-scale genetic mapping identifies the shared genetic landscape of rheumatic and cardiovascular disease

    Daniel Panyard1, Daniel Li2, Pik Fang Kho2, Rodrigo Guarischi-Sousa3, Jiayan Zhou2, Austin Hilliard4, Christie Bartels5, Philip Tsao2 and Themistocles Assimes2, 1Stanford University, Sunnyvale, CA, 2Stanford University, Palo Alto, CA, 3Palo Alto Veterans Institute for Research, Palo Alto, CA, 4VA Palo Alto Health Care, Palo Alto, CA, 5University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Patients with rheumatic conditions are at increased risk for cardiovascular (CV) problems, striking on average a decade before peers and conferring substantial morbidity and…
  • Abstract Number: 2136 • ACR Convergence 2025

    Confirming The Validity Of The New EULAR/ACR Classification Criteria For Pediatric Chronic Nonbacterial Osteomyelitis

    Greta Mastrangelo1, Edan Itzkovitz2, Katherine Sawicka3, Ingrid Goh4, Ari Bitnun5, Sevan Hopyan5, Paul Nathan2, Ronald laxer1 and Brian Feldman1, 1The Hospital for Sick Children, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, 3The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 4University of Toronto The Hospital for Sick Children, Toronto, ON, Canada, 5The Hospital for Sick Children, Toronto, Canada

    Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is a noninfectious autoinflammatory bone disease which remains a diagnosis of exclusion, as existing diagnostic criteria are not widely accepted.…
  • Abstract Number: 1823 • ACR Convergence 2025

    Genome-Wide DNA Methylation Analysis in Familial Mediterranean Fever

    Kader Cetin Gedik1, Desire Casares Marfil2, Busra Baser Taskin3, Elif Kilic Konte4, Sezgin Sahin4, Mckenna Bowes2, Ferhat Guzel5, Micol Romano6, Ozgur Kasapcopur7, Nuray Aktay Ayaz3, Erkan Demirkaya6 and Amr Sawalha2, 1UPMC Children's Hospital of Pittsburgh/University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3Istanbul University Medical School, Istanbul, Turkey, 4Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, 5Department of Research and Development, Ant Biotechnology, Istanbul, Turkey, 6University of Western Ontario, London, ON, Canada, 7Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey

    Background/Purpose: Familial Mediterranean fever (FMF) is an autoinflammatory disease most commonly associated with biallelic mutations in the MEFV gene. Patients carrying the same pathogenic variant…
  • Abstract Number: 1186 • ACR Convergence 2025

    Increased Adoption of IL-1 Pathway Inhibition and the Steroid-sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment From the RESONANCE Patient Registry

    Paul Cremer1, Michael Garshick2, Sushil Allen Luis3, Ajit Raisinghani4, Brittany Weber5, Vidhya Parameswaran6, Allison Curtis6, Sue Gibbons6, Allan Klein7 and John Paolini6, 1Cleveland Clinic, Shaker Heights, OH, 2NYU Langone Health, Tenafly, NJ, 3Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 4Division of Cardiology, Department of Medicine, Sulpizio Cardiovascular Center, University of California San Diego, San Diego, CA, 5Brigham and Women's Hospital, DEDHAM, MA, 6Kiniksa Pharmaceuticals, LEXINGTON, MA, 7Cleveland Clinic, Cleveland, OH

    Background/Purpose: Recurrent pericarditis (RP) is a chronic autoinflammatory disease mediated by IL-1 that requires long-term treatment. While the 2015 European Society of Cardiology Guidelines position…
  • Abstract Number: 0821 • ACR Convergence 2025

    Flipping The Switch – Classical Complement Activation closely linked to IFN-signalling in Stills Disease

    Freya Huijsmans1, Alejandra Bodelón de Frutos1, Lyanne Sijbers1, Susanne Benseler2, Joost Swart3, Rae Yeung4, Sebastiaan Vastert5 and Jorg van Loosdregt1, 1Pediatric Rheumatology & Immunology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, Utrecht, Netherlands, 2Cumming School of Medicine, Department of Pediatrics, University of Calgary, Calgary, AB, Canada, 3Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, 4The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 5University Medical Center Utrecht, Utrecht, Utrecht, Netherlands

    Background/Purpose: Stills disease (SD) is an autoinflammatory syndrome characterized by severe innate immune dysregulation. The complement system, an essential component of innate immunity, can drive…
  • Abstract Number: 0013 • ACR Convergence 2025

    Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases

    Xiaofeng Zhao1, Xiaoqing Liu1, Yuxi Yan2, Tiezheng Liu3, Yong Fu3, Yulan Hu2, Kangmin Zhou2, Minyun Zhou4, Yingying Hu2 and Shunwei Zhu2, 1State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), 2State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), 3State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), 4State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing

    Background/Purpose: B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that contributes to the regulation of T cell, B cell and dendritic cell…
  • Abstract Number: 2134 • ACR Convergence 2025

    Krebs von den Lungen-6 (KL-6) as a Potential Diagnostic Biomarker of Lung Disease in Pediatric Systemic Juvenile Idiopathic Arthritis: Preliminary Findings from a Multisite US Cohort

    Eileen Rife1, Lexi Auld2, Guihua Zhai3, Esraa Eloseily4, Grant Schulert5 and Yukiko Kimura6, 1University of Alabama at Birmingham, birmingham, AL, 2Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, 3UAB, Birmingham, 4UT Southwestern Children's Medical Center, Dallas, TX, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Hackensack Meridian School of Medicine, New York, NY

    Background/Purpose: Children with Systemic Juvenile Idiopathic Arthritis (SJIA) who develop lung disease (LD) are at significantly increased risk of serious complications and even death. Early…
  • Abstract Number: 1713 • ACR Convergence 2025

    Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients

    Mohamed Abdelsalam1, Menat Alla Ayman Ali Mahdy2, Maryam Lasheen3, Hadeer Hafez4, Nourhan Abouelella5, Abdelhfeez Moshrif6 and Mohamed Reda Awad7, 1Misr University For Science and Technology, 6 october, Al Jizah, Egypt, 2Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, 3Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, 46th October University, 6 october, Al Jizah, Egypt, 5Faculty of Medicine, Misr University for Science and Technology, 6 october, Al Jizah, Egypt, 6Al Azhar University, Asyut, Egypt, assyut, Asyut, Egypt, 7Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt

    Background/Purpose: Psoriatic arthritis (PsA) remains widely underdiagnosed and misdiagnosed worldwide, leading to delays in appropriate management and increased disease burden. While diagnostic delay has been…
  • Abstract Number: 1171 • ACR Convergence 2025

    VEXAS Syndrome Under the Lens: A prospective analysis of temporal disease patterns, biomarker Dynamics, and therapeutic efficacy

    Marta López1, Paula Garcia Escudero2, Berta Magallares3, Meritxell Salles Lizarzaburu4, Dolly Viviana Fiallo Suárez5, Iñigo Rúa-Figueroa6, Isla Morante Bolado7, Elena Aurrecoechea8, Eugenia Enriquez9, Carolina Merino10, Santos Castañeda11, Irene Monjo Henry12, César Antonio Egües Dubuc13, Elena María Oliver García14, Alicia Garcia15, Judit Font-Urgelles16, Cristina Corrales17, Lourdes Villalobos18, Alina-Lucica Boteanu19, Ignacio Vázquez Gómez20, Diego Dios21, Clara Garcia Belando22, Beatriz Frade Sosa23, Delia Reina24, Marta Ibañez25, Irene Carrion26, Maria Rodriguez27, cristiana Sieiro28, Francisco Javier Toyos29, Alberto Mariano30, Clara Moriano31, Rafael B. Melero-González32, Paloma Vela Casasempere33, Jose Alberto Miranda34, Giuliano Boselli35, Jose Angel Hernandez36, Ernesto Trallero37, Elena Riera Alonso38 and Jaime Calvo39, 1Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, 2H.U.Araba, Vitoria, 3Hospital de Sant Pau, Bareclona, 4Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, 5H.U. Doctor Negrín, Gran Canarias, 6Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, 7Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, 8H. Sierrallana, Santander, 9Clínica Universidad de Navarra, Madrid, Spain, 10Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, 11Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 12Hospital Universitario La Paz, Madrid, Spain, 13Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, 14H.C. U. Lozano Blesa, Zaragoza, 15Rheumatologist, La Laguna, Spain, 16Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 17HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, Santander, Spain, 18Ramon y Cajal Hospital, MADRID, Spain, 19H.U. Ramón y Cajal, Madrid, Spain, 20H.U. Doctor Peset, Valencia, 21H.U de A Coruña, A Coruña, Spain, 22H.C. U. Virgen de la arrizaca, Murcia, 23Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 24Complex Hospitalari Moisès Broggi, Barcelona, Spain, 25Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, 26Hospital del Mar, Barcelona, Spain, 27H. Clínico San Carlos, Madrid, Spain, 28Univrsity of Manchester, Manchester, United Kingdom, 29Virgen Macarena University Hospital,, Sevilla, Spain, 30Virgen del Rocío University Hospital, Sevilla, Spain, 31Hospital León, LEON, Castilla y Leon, Spain, 32COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, 33Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, 34C. H. U. Lucus Augusti, Lugo, Spain, 35Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, 36Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain, 37H. U. Vall d'Hebron, Barcelona, 38Hospital Universitari Mùtua Terrassa, Terrassa, Spain, 39Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain

    Background/Purpose: VEXAS syndrome is an adult-onset autoinflammatory disorder caused by somatic mutations in UBA1 gene, characterized by systemic inflammation and haematologic abnormalities. Evidence regarding its…
  • Abstract Number: 0779 • ACR Convergence 2025

    Interim Results of a Randomized Placebo Controlled Study of IL-1 Inhibitor Goflikicept in Patients With Familial Mediterranean Fever

    Olga Uhanova1, serdal Ugurlu2, Mikhail Kostik3, Tamara Sarkisyan4, Anna Yeghiazaryan4, Lidiya Lysenko5, Vilen Rameev5, Omer Karadag6, Valentina Vardanyan7, Veli Yazisiz8, Tatiana Sotnikova9, Vyacheslav Podsvirov1, Alina Egorova10, Daria Bukhanova10, Sergey Grishin10, Tolga Tuncel11, Mikhail Samsonov10 and Ahmet Gul12, 1Terafarm LLC, Stavropol, Russia, 2Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 4Center of Medical Genetics and Primary Health Care LTD, Yerevan, Armenia, 5Sechenov’s 1st State Moscow Medical University, Moscow, Russia, 6Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, 7Ecosense Diagnostic Center, Yerevan, Armenia, 8Akdeniz University, Faculty of Medicine, Antalya, Turkey, 9State Budgetary Institution of Healthcare of Moscow Multispeciality Hospital named after S.P. Botkin of the Moscow City and Sechenov University, Moscow, Russia, 10R-Pharm JSC, Moscow, Russia, 11TRpharm, Istanbul, Turkey, 12Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey

    Background/Purpose: Goflikicept (GFC; RPH-104) is a novel fusion protein inhibiting interleukin-1 (IL-1). This study aimed to investigate its efficacy and safety in IL-1β-driven monogenic autoinflammatory…
  • Abstract Number: 0586 • ACR Convergence 2025

    Immune Checkpoint agonists: A New horizon for treatment of psoriatic arthritis

    Siba Raychaudhuri1, Christine Abria2 and Smriti K Raychaudhuri3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2Sacramento VA Medical Center, Mather, CA, 3Sacramento VA Medical Center, Davis, CA

    Background/Purpose: Check point inhibitor PD-1 (programmed death protein 1) is upregulated during T lymphocyte activation and is important for limiting the duration of activation. Thus,…
  • Abstract Number: 2667 • ACR Convergence 2025

    Amyloidosis Secondary to Familial Mediterranean Fever: Machine Learning Based Prediction Models

    Berkay Aktas1, Enes Azman1, Yusuf Ecren Oner2, kadir Kaya2, husnu Mert Yuksel3, Ali Hosgel2, Dilan Karahan2, Zehra Beyza Coban2, Kerem parlar4, Ozgur Can Kilinc1, Beste Acar1 and serdal Ugurlu5, 1Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, 4Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, İstanbul, Turkey, 5Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disease caused by MEFV mutations. Amyloidosis remains its most serious complication, with several risk factors reported…
  • Abstract Number: 2129 • ACR Convergence 2025

    Distinct endotypes of SURF associated with clinical phenotypes, inflammatory cytokines, and treatment responses

    Marci Macaraeg1, Nadine Saad2, Tiphanie Vogel3, Fatma Dedeoglu4, Kyle McBrearty4, Qin Sun5, Chunyan Liu5 and Grant Schulert5, 1University of Arizona College of Medicine, Tucson, AZ, 2University of Michigan, Ann Arbor, MI, 3Baylor College of Medicine, Houston, TX, 4Boston Children's Hospital, Boston, MA, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Syndrome of Undifferentiated Recurrent Fevers (SURF) refers to patients with recurrent fevers who do not meet clinical or classification criteria for Periodic Fevers, Aphthous…
  • Abstract Number: 1669 • ACR Convergence 2025

    Development and Validation of Minimal Disease Activity and Disease Flare for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach

    Farzana Nuruzzaman1, Natalie Rossenwasser2, Xing Wang3, Ava Klein3, Ian Muse4, Erin Balay-Dustrude5, Megan Nguyen6, Emily Deng3, Jonathan Akikusa7, Matthew Basiaga8, Lindsey Bergstrom9, Fatma Dedeoglu10, Bin Huang11, Jenna King12, Sivia Lapidus13, Tzielan Lee14, Aleksander Lenert15, Cassandra Levesque16, Lillian Lim17, Kimberly Martin18, Elizabeth Murray19, Melissa Oliver20, Karen Onel21, Seza Özen22, Lauren Potts23, Sara M. Stern24, Robin Villaverda25, Eveline Wu26, Ronald laxer27, Polly Ferguson28, Daniel Lovell29 and Yongdong (Dan) Zhao30, 1Stony Brook Children's Hospital, Stony Brook, NY, 2Seattle Children's Hospital, Seattle, WA, 3Seattle Children's Hospital, Seattle, 4University of Washington, Department of Pediatrics, Seattle Children's Hospital, Seattle, 5University of Washington, Seattle, WA, 6Seattle Children’s Research Institute, Seattle, 7The Royal Children's Hospital, Parkville, Victoria, Australia, 8Mayo Clinic, Rochester, MN, 9Patient/parent research partner, Harpswell, ME, 10Boston Children's Hospital, Boston, MA, 11Cincinnati Children's Hospital, Cinciannati, OH, 12Patient/parent Research Partner, Planation, FL, 13Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Montclair, NJ, 14Stanford University School of Medicine, Palo Alto, CA, 15Iowa Carver College of Medicine, Iowa City, IA, 16Patient/parent research partners, DC district, DC, 17University of Alberta, Edmonton, AB, Canada, 18Patient/parent research partners, Houston, TX, 19Patient/parent research partners, Lynnwood, WA, 20Indiana University, Indianapolis, IN, 21HSS, New York, NY, 22Hacettepe University Medical Faculty, Ankara, Turkey, 23Patient/parent research partners, Santa Cruiz, CA, 24University of Utah, Salt Lake City, UT, 25Patient/parent research partners, Thorton, CO, 26UNC Chapel Hill, Chapel Hill, NC, 27The Hospital for Sick Children, Toronto, ON, Canada, 28University of Iowa Carver College of Medicine, Iowa City, IA, 29Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 30Seattle Children’s Research Institute, Redmond, WA

    Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an inflammatory bone disease that can result in bone destruction/deformity, persistent bone pain and pathological fractures. Due to the…
  • Abstract Number: 1170 • ACR Convergence 2025

    A20 Haploinsufficiency (HA20): TNFAIP3 Mutation Prevalence In A Clinically Compatible Cohort

    María Alonso de Francisco1, Emiliano González Vioque2, Pablo Navarro Palomo3, Maria Machattou4, Carlota Navarro Joven4, Laura Ramos Ortiz de Zarate4, Alejandro Martínez5, Adriana Martín Bescós4, Paula Mazo4, María Concepción Sánchez Fernández4, Andrea Liso Andrino4, Maria Carmen Barbadillo Mateos6, JESUS SANZ SANZ7, Hildegarda Godoy Tundidor4, Jose Campos8, Monica Fernandez Castro9, Blanca García Magallón4, Olga Rusinovich10, Laura Nuño11, Jose Luis Andreu12 and Carolina Merino13, 1H. U. Puerta de Hierro Majadahonda, Tres Cantos, Spain, 2Hospital Puerta de Hierro Majadahonda, Madrid, Spain, 3Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain, 4Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 5Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Afghanistan, 6Public, Madrid, Spain, 7SERMAS, Madrid, Spain, 8Hospital Universitario Principe de Asturias, Madrid, Spain, 9PUERTA DE HIERRO HOSPITAL, Madrid, Spain, 10Puerta de Hierro Majadahonda University Hospital, Boadilla del Monte, Spain, 11Hospital Universitario Puerta de Hierro, Madrid, Spain, 12Hospital Universitario Puerta de Hierro, Majadahonda, Spain, 13Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain

    Background/Purpose: Haploinsufficiency of A20 (HA20) is a disease at the crossroads between autoinflammation and autoimmunity, caused by heterozygous mutations in TNFAIP3, which encodes the A20…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology